Stryker Co. (NYSE:SYK) Shares Bought by Abner Herrman & Brock LLC

Abner Herrman & Brock LLC boosted its stake in Stryker Co. (NYSE:SYK) by 1.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,880 shares of the medical technology company’s stock after acquiring an additional 475 shares during the period. Abner Herrman & Brock LLC’s holdings in Stryker were worth $11,478,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SYK. Dunhill Financial LLC grew its holdings in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the last quarter. Darwin Wealth Management LLC purchased a new stake in Stryker during the 3rd quarter worth about $36,000. Crews Bank & Trust acquired a new position in Stryker in the 4th quarter valued at about $39,000. Hara Capital LLC acquired a new stake in shares of Stryker during the 3rd quarter worth about $42,000. Finally, HBW Advisory Services LLC purchased a new stake in shares of Stryker during the third quarter worth about $42,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.50% of the stock is currently owned by insiders.

Stryker Stock Up 0.1 %

Shares of Stryker stock opened at $390.90 on Monday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average price of $376.68 and a 200 day moving average price of $363.02. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The firm has a market cap of $149.02 billion, a P/E ratio of 50.37, a P/E/G ratio of 2.78 and a beta of 0.96.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm earned $3.46 earnings per share. On average, sell-side analysts forecast that Stryker Co. will post 13.5 earnings per share for the current fiscal year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were issued a dividend of $0.84 per share. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date was Tuesday, December 31st. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s payout ratio is presently 43.30%.

Analyst Ratings Changes

SYK has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “buy” rating and set a $442.00 price target on shares of Stryker in a research note on Wednesday, January 29th. BTIG Research upped their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group upped their price target on shares of Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research report on Thursday. Royal Bank of Canada increased their target price on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Finally, StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research note on Thursday. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $419.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.